Rigel Pharmaceuticals to unveil RET fusion-positive tumor findings at ESMO 2026

Traders Union
All News
Business & Wealth
Companies
Rigel unveils pralsetinib data at ESMO

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

20.10.2026

Rigel Pharmaceuticals to unveil RET fusion-positive tumor findings at ESMO 2026 — Rigel unveils pralsetinib data at ESMO

Rigel Pharmaceuticals announced plans for both oral and poster presentations at the ESMO Congress 2026, focusing on clinical data for pralsetinib. The presentations will cover pralsetinib’s impact on patients with RET fusion-positive solid tumors, including those with thyroid cancer and non-small cell lung cancer.

The announcement signals Rigel Pharmaceuticals’ engagement with the oncology research community and commitment to advancing targeted cancer therapies.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

The end of Bitcoin’s growth era: Why prominent investors doubt its future

By Olena Litvinenko
13 hours ago

The end of Bitcoin’s growth era: Why prominent investors doubt its future

Editors' Picks

WeFi CEO: Banks are overstating the threat from stablecoins

By Eugene Komchuk
14 hours ago

WeFi CEO: Banks are overstating the threat from stablecoins

Editors' Picks

HSBC’s warning signs point to a bigger risk for global banks

By Dmytro Kharkov
16 hours ago

HSBC’s warning signs point to a bigger risk for global banks

Editors' Picks

All Editors' Top Picks

Latest Rigel News

Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month

By Eugene Komchuk
01.09.2026

Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month

Companies

VEPPANU commercialized as new treatment class, Rigel Pharmaceuticals reveals

By Artem Shendetskii
14.08.2026

VEPPANU commercialized as new treatment class, Rigel Pharmaceuticals reveals

Companies

Rigel Pharmaceuticals posts Q2 2026 earnings and schedules results webcast

By Ivan Andriyenko
04.08.2026

Rigel Pharmaceuticals posts Q2 2026 earnings and schedules results webcast

Companies

Olena Litvinenko
13 hours ago

The end of Bitcoin’s growth era: Why prominent investors doubt its future

Eugene Komchuk
14 hours ago

WeFi CEO: Banks are overstating the threat from stablecoins

Dmytro Kharkov
16 hours ago

HSBC’s warning signs point to a bigger risk for global banks

Anastasiia Chabaniuk
Yesterday

Why do crypto companies want their own banks?

Mikhail Vnuchkov
Yesterday

Between record and bubble: How Anthropic is approaching its IPO

Hanna Syniavska
16 min ago

Anthropic moves forward with IPO plans after AI agent setbacks, John Legere notes

Mikhail Vnuchkov
36 min ago

Lance Lambert: Mortgage purchase applications hover near lowest levels in 30 years

Mykhailo Ihnatenko
46 min ago

Real estate share dropped from 38 percent to 10 percent before 2021 action, Mike Bird notes

Yaroslav Dmytrenko
1 hour ago

Will Hutton: Concerns grow despite £20bn National Wealth Fund announcement

Igor Krasulya
2 hours ago

TRX options become accessible to more people on Blockchain, Justin Sun notes

Top News

Olga Shendetskaya
9 hours ago

Bank of Canada raises rates for first time in over three years

Bank of Canada raises rates for first time in over three years

Eugene Komchuk
10 hours ago

Google develops a Bitcoin custody service

Google develops a Bitcoin custody service

Andrey Mastykin
11 hours ago

Oil prices jump amid new threats to Saudi energy infrastructure

Oil prices jump amid new threats to Saudi energy infrastructure

Hanna Syniavska
12 hours ago

Nasdaq futures rise as SK Hynix earnings fuel chip rally

Nasdaq futures rise as SK Hynix earnings fuel chip rally

Ivan Andriyenko
14 hours ago

Robinhood shares drop 8% as crypto slump weighs on earnings

Robinhood shares drop 8% as crypto slump weighs on earnings

Top 5 companies for you

United States

Live News

Aleksandra Chaikina
Now

DTCC launches securities tokenization service with JPMorgan and Citi

Anton Kharitonov
Now

EUR/USD remains under pressure near 1.1125 ahead of Fed rate decision

Hanna Syniavska
Now

Turkey cancels Tera Yatirim license amid $100 billion market rout

Mykhailo Ihnatenko
Now

AMD stock rebounds as Meta tests Helios systems and Oracle expands EPYC use

Mykhailo Ihnatenko
Now

Ethereum price prediction: Can $2,300 support prevent another liquidation wave?

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.